Share on StockTwits

Gilead Sciences (NASDAQ:GILD) CEO John C. Martin unloaded 140,625 shares of Gilead Sciences stock on the open market in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $84.84, for a total value of $11,930,625.00. Following the completion of the transaction, the chief executive officer now directly owns 4,429,387 shares of the company’s stock, valued at approximately $375,789,193. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

GILD has been the subject of a number of recent research reports. Analysts at Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research note on Monday. They now have a $75.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, May 29th. Finally, analysts at Deutsche Bank raised their price target on shares of Gilead Sciences from $135.00 to $142.00 in a research note on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $94.91.

Gilead Sciences (NASDAQ:GILD) traded up 0.92% on Thursday, hitting $87.90. The stock had a trading volume of 9,124,187 shares. Gilead Sciences has a 52-week low of $51.63 and a 52-week high of $87.88. The stock’s 50-day moving average is $81.55 and its 200-day moving average is $77.9. The company has a market cap of $135.0 billion and a P/E ratio of 32.26. Gilead Sciences also was the recipient of a significant drop in short interest in the month of June. As of June 13th, there was short interest totalling 92,230,036 shares, a drop of 2.0% from the May 30th total of 94,135,575 shares. Based on an average trading volume of 10,372,330 shares, the short-interest ratio is presently 8.9 days. Currently, 6.0% of the shares of the company are sold short.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $1.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.85 by $0.63. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter last year, the company posted $0.48 earnings per share. Gilead Sciences’s revenue was up 97.5% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $6.28 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.